Gamma Knife Surgery for Residual or Recurrent Craniopharyngioma After Surgical Resection: A Multi-institutional Retrospective Study in Japan.

craniopharyngioma gamma knife radiosurgery

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
12 Feb 2020
Historique:
entrez: 24 3 2020
pubmed: 24 3 2020
medline: 24 3 2020
Statut: epublish

Résumé

Objective The optimal treatment for a craniopharyngioma has been controversial. Complete resection is ideal, but it has been difficult to obtain total resection in many cases because of intimate proximity to critical structures such as the optic pathway, hypothalamus, and pituitary gland. A growing number of studies have demonstrated the utility of radiosurgery in controlling residual or recurrent craniopharyngioma. However, most of them are small series. The aim of this multi-institutional study was to clarify the efficacy and safety of Gamma Knife (Elekta, Stockholm, Sweden) surgery for patients with a craniopharyngioma. Methods This was a multi-institutional retrospective study by 16 medical centers of the Japan Leksell Gamma Knife Society. Data on patients with craniopharyngiomas treated with Gamma Knife Surgery (GKS) between 1991 and 2013 were obtained from individual institutional review board-approved databases at each center. A total of 242 patients with craniopharyngioma were included in this study. The mean age of the patients was 41 (range, 3 to 86) years. The median follow-up time was 61.4 months (range, 3 to 180 months). The mean radiosurgery target volume was 3.1 ml (range, 0.03-22.3 ml), and the mean marginal dose was 11.4 Gy (range, 8-20.4 Gy). Results Two-hundred twenty patients were alive at the time of the last follow-up visit. The three-, five-, and 10-year overall survival rates after GKS were 95.4%, 92.5%, and 82.0%, respectively. The three-, five-, and 10-year progression-free survival rates after GKS were 73.1%, 62.2%, and 42.6% respectively. The rate of radiation-induced complications was 6.2%. Conclusion GKS is effective for controlling the tumor growth of craniopharyngiomas with an acceptable complication rate.

Identifiants

pubmed: 32201653
doi: 10.7759/cureus.6973
pmc: PMC7075476
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e6973

Informations de copyright

Copyright © 2020, Tsugawa et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

World Neurosurg. 2019 Jan 3;:
pubmed: 30610976
J Neurooncol. 2018 Oct;140(1):135-143
pubmed: 29987747
Radiat Oncol. 2014 Sep 16;9:203
pubmed: 25227427
Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):189-95
pubmed: 8407391
J Clin Neurosci. 2012 Jul;19(7):1005-8
pubmed: 22595354
Stereotact Funct Neurosurg. 2009;87(6):360-7
pubmed: 19752595
J Neurosurg. 1986 Jul;65(1):22-7
pubmed: 3712025
Radiother Oncol. 2007 Jan;82(1):90-5
pubmed: 17161483
J Neurosurg. 1990 Jul;73(1):3-11
pubmed: 2352020
Pituitary. 2006;9(4):323-6
pubmed: 17080265
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):64-71
pubmed: 20005637
J Neurosurg. 1998 Oct;89(4):547-51
pubmed: 9761047
Neurosurgery. 2010 Apr;66(4):688-94; discussion 694-5
pubmed: 20190668
J Neurooncol. 2012 Feb;106(3):571-7
pubmed: 21861196
J Neurooncol. 2010 Jun;98(2):239-47
pubmed: 20422439
Radiother Oncol. 1993 Apr;27(1):13-21
pubmed: 8327728
J Clin Neurosci. 1999 Nov;6(6):527-30
pubmed: 18639199
Nagoya J Med Sci. 2012 Feb;74(1-2):141-7
pubmed: 22515120
J Neurosurg. 2014 Dec;121 Suppl:167-78
pubmed: 25434950
Med Pediatr Oncol. 2003 Apr;40(4):214-8
pubmed: 12555247
Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):255-63
pubmed: 10760417
J Neurosurg. 1999 Feb;90(2):251-7
pubmed: 9950495
Neurosurgery. 2010 Nov;67(5):1341-9; discussion 1349
pubmed: 20871436
J Neurosurg. 1999 Feb;90(2):237-50
pubmed: 9950494
J Neurosurg. 2007 Jan;106(1 Suppl):3-12
pubmed: 17233305
J Neurosurg. 2002 Dec;97(5 Suppl):613-22
pubmed: 12507107
Pituitary. 2009;12(4):352-9
pubmed: 19130248
J Neurosurg. 1985 May;62(5):648-56
pubmed: 3989587
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):492-9
pubmed: 12243827

Auteurs

Takahiko Tsugawa (T)

Neurosurgery, Nagoya Radiosurgery Center, Nagoya Kyoritsu Hospital, Nagoya, JPN.

Tatsuya Kobayashi (T)

Neurosurgery, Nagoya Radiosurgery Center, Nagoya Kyoritsu Hospital, Nagoya, JPN.

Toshinori Hasegawa (T)

Neurosurgery, Komaki City Hospital, Komaki, JPN.

Yoshiyasu Iwai (Y)

Neurosurgery, Osaka City General Hospital, Osaka, JPN.

Shigeo Matsunaga (S)

Neurosurgery, Yokohama Rosai Hospital, Yokohama, JPN.

Masaaki Yamamoto (M)

Neurosurgery, Mito Gammahouse, Katsuta Hospital, Hitachinaka, JPN.

Motohiro Hayashi (M)

Neurosurgery, Tokyo Women's Medical University Hospital, Tokyo, JPN.

Hiroyuki Kenai (H)

Neurosurgery, Nagatomi Neurosurgical Hospital, Oita, JPN.

Tadashige Kano (T)

Neurosurgery, Kano Neurosurgery Clinic, Maebashi, JPN.

Hisae Mori (H)

Neurosurgery, National Cerebral and Cardiovascular Center, Suita, JPN.

Osamu Nagano (O)

Neurosurgery, Chiba Cerebral and Cardiovascular Center, Ichihara, JPN.

Seiko Hasegawa (S)

Neurosurgery, Kuroishi General Hospital, Kuroishi, JPN.

Akira Inoue (A)

Neurosurgery, Yamagata Prefectural Central Hospital, Yamagata, JPN.

Yasushi Nagatomo (Y)

Neurosurgery, Kouseikai Takai Hospital, Tenri, JPN.

Shinji Onoue (S)

Neurosurgery, Ehime Prefectural Central Hospital, Matsuyama, JPN.

Manabu Sato (M)

Neurosurgery, Rakusai Shimizu Hospital, Kyoto, JPN.

Soichiro Yasuda (S)

Neurosurgery, Shiroyama Hospital, Habikino, JPN.

Classifications MeSH